Posted by on May 21, 2018 12:08 pm
Categories: Crispr Articles

Source: CRSP Stock Is Leading With This Revolutionary Technology

CRSP Stock Is Leading

CRISPR Stock Is Volatile but Promising

Beta thalassemia, hemophilia, Hurler syndrome, Cystic Fibrosis…

Difficult names to read. They are diseases that are very difficult to cure, and they claim a significant number of lives around the world.

Scientists, however, have made a breakthrough that exploits the human body’s natural defense mechanism that protects bacteria against viral infections. A handful of companies are working on this technology, and CRISPR Therapeutics AG (NASDAQ:CRSP) is one of the leading players.

CRISPR Therapeutics works on gene-based medicines for serious human diseases. The company is focused on developing its revolutionary technology called “CRISPR/Cas9,” which can be used to edit human genes.

CRISPR stands for “clustered, regularly interspaced short palindromic repeats,” and Cas9 stands for “CRISPR-associated protein-9.”

CRISPR/Cas9 can be used to disrupt, correct, or regulate genes at the molecular level in order to cure patients.

The company has established a portfolio of therapeutic programs across a broad range of disease areas.

Genetic disease treatment is a high-potential market, and this bodes well for CRISPR stock.

According to MarketsandMarkets Research Private Ltd, the global genome editing market is expected to grow from almost $3.2 billion in 2017 to almost $6.3 billion by 2022. (Source: “Genome Editing/Genome Engineering Market by Technology … Global Forecast 2022,” MarketsandMarkets Research Private Ltd, last accessed May 18, 2018.)

Gene editing is likely to change the way diseases are treated, and CRISPR Therapeutics is the dominating player in this field.

The company announced its first-quarter 2018 results this month. CRISPR has strong pipeline of cell therapies and a robust financial position. As of March 31, the company had $341.8 million in cash.

CRISPR Therapeutics is making rapid progress with its lead program, “CTX001,” which is for treating beta-thalassemia and sickle cell disease. Its first clinical trial application has been accepted, and trials are expected to begin in the second half of 2018.

CRISPR stock recently shot up by more than 13% to touch another record high. Over the last year, the stock has gained almost 300%.

The following CRSP stock chart shows this spectacular run.

crsp stock chart

Chart courtesy of

Analyst Take

Gene-based medicine is a field with great potential. It will determine the future course of next-generation therapies. CRISPR Therapeutics is well positioned to gain from this trend.

As CRISPR stock hovers near record highs, investors should consider it on any sign of weakness.

Published at Mon, 21 May 2018 12:00:24 +0000